6 results about "Sulindac" patented technology

This invention discloses a method for preparing sulindac. The method involves first performing an Arbuzov reaction and a Wittig-Horner reaction sequentially to obtain 6-fluoro-3-(p-methylthiobenzyl)-2-methyl-1H-indene. 6-fluoro-3-(p-methylthiobenzyl)-2-methyl-1H-indene undergoes a condensation dehydration reaction with glyoxylic acid, followed by double bond rearrangement under acidic conditions to obtain (Z)-5-fluoro-2-methyl-1-(p-methylthiobenzyl)-1H-indene-3-acetic acid. Finally, it undergoes a single oxidation reaction with an oxidant to obtain sulindac. The raw materials and excipients used in this invention are readily available, and the entire reaction route is short, the reaction conditions are mild, the operation is safe and simple, the yield is high, the purity is high, the production cost is low, and the emissions of waste are minimal, conforming to green industrial production standards. The total yield of the obtained sulindac product is over 75%, which is conducive to industrial production.

A new use of 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl] acetic acid (sulindac) of the formula 1 for making the pharmaceutical preparations for the treatment of difficult healing different types of wounds in patients with diabetes.The medical use of 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl] acetic acid (sulindac) of the formula 1 shown in the FIG. 1 for the preparation of pharmaceutical formulations for the treatment of difficult healing different types of wounds in patients with diabetes is disclosed.

The invention discloses a method for separating sulindac and impurities thereof. The method comprises the step of determining impurities of sulindac in a test sample by using a high performance liquid chromatograph. The separation and detection method disclosed by the invention is good in separation degree, simple to operate, short in peak appearance time and short in detection time, and also has good method reproducibility and stability.

The invention relates to the technical field of medicine, and particularly discloses sulindac external gel emplastrum and application thereof.The sulindac and a functional matrix with hydrophilic amino functional groups are subjected to molecular self-assembly, the functional matrix and carboxyl of the sulindac are subjected to non-covalent interaction through hydrogen bonds, ionic bonds and the like, and the sulindac external gel emplastrum is obtained. The stable micromolecular hydrogel with the three-dimensional network structure is spontaneously formed. The hydrogel can be prepared into an external gel emplastrum through simple compounding, the three-dimensional network structure endows the gel emplastrum with appropriate viscosity and skin adhesiveness, and the gel emplastrum can be tightly attached to the skin after being smeared on painful parts (such as joints and muscles) and is not prone to falling off due to movement. The preparation process has the advantages of simplicity and convenience in operation, economy and high efficiency, complex equipment is not needed in the micromolecule self-assembly process, the gel emplastrum can be compounded only through simple mixing, industrial production is facilitated, and the preparation method has high clinical conversion value and application potential.

The invention provides sulindac as a GPR119 agonist and application of sulindac in preparation of a product for improving IFPD, and belongs to the technical field of new application of drugs. The invention particularly provides application of sulindac as a non-steroidal anti-inflammatory drug in preparation of a GPR119 agonist product and application of sulindac in preparation of a product for improving fat deposition in pancreas. A sulindac intervention experiment shows that the expression of the sulindac on GPR119 / CaM / AKT / Foxo1 pathway protein of a C57BL / 6J mouse tends to a normal level, which indicates that the sulindac has the potential as a GPR119 agonist and also has the effect of improving IPFD.

The present application relates to the technical field of pharmaceutical preparation, and discloses a sulindac tablet composition and a preparation method thereof; the sulindac tablet composition comprises sulindac, a filler, a binder, a disintegrant and a lubricant, the binder is povidone K30, the disintegrant is corn starch, and the preparation method comprises the following steps: (1) uniformly mixing the prescription amount of sulindac, the disintegrant and the filler; (2) preparing the binder into a binder solution and performing wet granulation; (3) performing whole granulation; and (4) performing total mixing and tablet pressing. The sulindac tablet composition has simple process and stable quality, and compared with the original research, the dissolution stability under high-temperature and high-humidity conditions is better than that of the original research.